Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 03:10PM GMT
Release Date Price: R$52.98 (-1.50%)
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Great. Well, thanks, everybody, for joining us. I'm Terence Flynn, the U.S. pharma analyst here at Morgan Stanley. We're very pleased to be hosting Eli Lilly today. Joining us from the company is Anat Ashkenazi, the company's CFO. Thank you so much, Anat, for being here. It's great to see you in person.

Anat Ashkenazi
Eli Lilly and Company - Senior VP & CFO

Absolutely.

Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions & Answers

Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Well, again, obviously, a very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot